TuHURA Biosciences (HURA) Income from Non-Controlling Interests (2012 - 2026)
TuHURA Biosciences' (HURA) quarterly Income from Non-Controlling Interests came in at $2000.0 in Q1 2026, little changed quarter-over-quarter from $2000.0 in Q4 2025.
TuHURA Biosciences (HURA) Income from Non-Controlling Interests (2012 - 2026) Analysis & Trends
TuHURA Biosciences' Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at $2000.0 for Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to $2000.0 in Q1 2026; TTM through Mar 2026 was -$10903.0, a N/A change from a year earlier, with the FY2025 full-year figure at $5000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests held at $2000.0 in Q1 2026 per HURA's latest filing, from $2000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $3000.0 in Q3 2025 and bottomed at $2000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | TuHURA Biosciences | 132.62 Mn | 132.62 Mn | - | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Mar 31, 2012 | -17,903.00 |